ArticleInternational journal of colorectal disease2008
Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up.
Article in International journal of colorectal disease, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.Frontiers in immunology · 2024Pooled it
- Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Pooled it
- Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.World journal of gastroenterology · 2013Pooled it
- Autoantibodies against p53, MMP-7, and Hsp70 as Potential Biomarkers for Detection of Nonmelanoma Skin Cancers.Disease markers · 2021Article
- Significance of Serum p53 Antibody as a Tumor Marker in Colorectal Cancer.Disease markers · 2019Article
- Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer.Molecular and clinical oncology · 2017Article
- The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.Surgery today · 2017Article
- Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer.Cancer science · 2017Article
- Differential Immune Reactivity Pattern of SW48 and SW1116 Colorectal Cancer Cell Lines with Colorectal Cancer Patients Sera.Advanced biomedical research · 2017Article
- Article
- Serum anti-p53 antibody as a tumour marker for colorectal cancer screening.Ecancermedicalscience · 2015Article
- Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients.Surgery today · 2014Article
- Secreted recombinant P53 protein from Pichia pastoris is a useful antigen for detection of serum p53: autoantibody in patients with advanced colorectal adenocarcinoma.Molecular biology reports · 2013Article
- Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer.British journal of cancer · 2013Article
- Prognostic significance of p53-expression in colorectal carcinoma as measured by a luminometric immunoassay.German medical science : GMS e-journal · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic significance of anti-53 autoantibody in colorectal cancer (CRC) patients is unclear due to measurement of overall rather than disease-specific survival and generally short follow-up periods in many studies. We aim to investigate prognostic significance of anti-p53 auto-antibodies in a study with long-term follow-up (minimum 5 years).
methodsELISA for anti-p53 autoantibody was assayed in serum from 92 patients with CRC and 28 controls.
resultsAnti-p53 autoantibody was found in 20 patients (21.7%) and none of the controls. No difference in Dukes' (A/B vs. C/D), Stage (I/II vs. III/IV), T1/2 vs. T3/4, N0 vs. N1/2, M0 vs. M1, poor vs. well/moderate differentiation and proximal vs. distal CRC was observed. Median overall survival was 62 months and median disease-specific survival was 73 months. Dukes' C/D, Stage III/IV, N1/2 and M1 were associated with poor disease-specific survival in univariate analysis. Stage III/IV was an independent prognostic factor in overall and disease-free survival in multivariate analysis. Anti-p53 autoantibody sero-positivity did not influence overall (p = 0.980) or disease-specific survival (p = 0.874). Median overall survival in anti-p53 autoantibody positive patients was 62 months vs. 60 months in anti-53 autoantibody negative patients. Median disease-specific survival in anti-p53 autoantibody positive patients was 73 months vs. 82 months.
conclusionAnti-p53 autoantibody is not related to clinical parameters of CRC and has no prognostic significance in long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.